@article{60c0aa01357d4ec884e10239bdc3e165,
title = "Elevated prevalence of moderate-to-severe hepatic steatosis in World Trade Center General Responder Cohort in a program of CT lung screening",
abstract = "Background and aims: To determine the prevalence of moderate-to-severe hepatic steatosis (HS) and associated risk factors in members of the World Trade Center (WTC) General Responder Cohort (GRC) who qualify for low-dose non-contrast computed tomography for lung cancer screening and compare them to non-WTC participants in the same screening program. Methods: All participants gave written informed consent before participating in this IRB-approved study. Clinical variables and laboratory values were recorded. Hepatic attenuation measurement (Hounsfield unit; HU) was measured on low-dose computed tomography (LDCT) and a threshold attenuation value <40HU indicated moderate-to-severe HS. Bivariate and multivariable linear and logistic regression analyses were performed. Propensity scores (PS) were calculated and inverse probability weighting (IPW) was used to adjust for potential confounders when comparing the WTC with non-WTC participants. Results: The prevalence of moderate-to-severe HS was 16.2% among 154 WTC participants compared to 5.3% among 170 non-WTC participants. In WTC members, moderate-to-severe HS was associated with higher BMI, higher laboratory liver function tests, and former smoking status. Using PS analysis and IPW to account for potential confounders, the odds ratio for moderate-to-severe HS was 3.4-fold higher (95% confidence interval: 1.7–6.7) in the WTC participants compared with non-WTC participants. Moderate-to-severe HS was also associated with higher BMI and former smoker status. Conclusion: Prevalence of moderate-to-severe HS was >3-fold higher in the WTC-GRC group than in other participants.",
keywords = "Airborne particulate matter, CT screening, Liver attenuation, Liver disease",
author = "Xiangmeng Chen and Teng Ma and Rowena Yip and Perumalswami, {Ponni V.} and Branch, {Andrea D.} and Sara Lewis and Michael Crane and Yankelevitz, {David F.} and Henschke, {Claudia I.}",
note = "Funding Information: Dr. Yankelevitz is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF), are non-exclusively licensed to General Electric. As an inventor of these patents, Dr. Yankelevitz is entitled to a share of any compensation which CRF may receive from its commercialization of these patents. He is also an equity owner in Accumetra, a privately held technology company committed to improving the science and practice of image-based decision making (7 Corporate Drive, Clifton Park, NY 12065; Tel: 518–280-7530; http://accumetra.com/ ). Dr. Yankelevitz also serves on the advisory board of GRAIL (1525 O'Brien Drive, Menlo Park, CA 94025; Tel: 650–542-0372; https://grail.com/ ). Dr. Henschke is the President and serves on the board of the Early Diagnosis and Treatment Research Foundation. She receives no compensation from the Foundation. The Foundation is established to provide grants for projects, conferences, and public databases for research on early diagnosis and treatment of diseases. Dr. Claudia Henschke is also a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest which are owned by Cornell Research Foundation (CRF). Since 2009, Dr. Henschke does not accept any financial benefit from these patents including royalties and any other proceeds related to the patents or patent applications owned by CRF. Other authors declare no conflicts of interest. Funding Information: This manuscript is sponsored by the Flight Attendant Medical Research Institute (FAMRI) and the National Institute for Occupational Safety and Health (NIOSH) U01 OH011489 . Funding Information: None. This manuscript is sponsored by the Flight Attendant Medical Research Institute (FAMRI) and the National Institute for Occupational Safety and Health (NIOSH) U01 OH011489. This work was performed at the Icahn School of Medicine at Mount Sinai in New York, NY. We reviewed baseline LDCT scans of the chest of all WTC participants who qualified for and participated in the National Institute of Occupational Safety and Health (NIOSH)-approved early lung cancer screening program between Feb 2016 and Jan 2017. Written informed consent was obtained according to a HIPAA-compliant protocol approved by the Icahn School of Medicine at Mount Sinai IRB. None. Publisher Copyright: {\textcopyright} 2019",
year = "2020",
month = apr,
doi = "10.1016/j.clinimag.2019.12.009",
language = "English",
volume = "60",
pages = "237--243",
journal = "Clinical Imaging",
issn = "0899-7071",
publisher = "Elsevier Inc.",
number = "2",
}